Search Results

There are 9318 results for: content related to: The risk of coronary heart disease in type 2 diabetic patients exposed to thiazolidinediones compared to metformin and sulfonylurea therapy

  1. You have full text access to this OnlineOpen article
    Inhibition of endotrophin, a cleavage product of collagen VI, confers cisplatin sensitivity to tumours

    EMBO Molecular Medicine

    Volume 5, Issue 6, June 2013, Pages: 935–948, Jiyoung Park, Thomas S. Morley and Philipp E. Scherer

    Version of Record online : 30 APR 2013, DOI: 10.1002/emmm.201202006

  2. Use of thiazolidinediones and risk of osteoporotic fracture: disease or drugs?

    Pharmacoepidemiology and Drug Safety

    Volume 21, Issue 5, May 2012, Pages: 507–514, Marloes T. Bazelier, Arlene M. Gallagher, Tjeerd-Pieter van Staa, Cyrus Cooper, Hubert G. M. Leufkens, Peter Vestergaard and Frank de Vries

    Version of Record online : 6 MAR 2012, DOI: 10.1002/pds.3234

  3. Thiazolidinedione insulin sensitizers and the heart: a tale of two organs?

    Diabetes, Obesity and Metabolism

    Volume 10, Issue 4, April 2008, Pages: 312–328, R. E. Buckingham and A. Hanna

    Version of Record online : 16 JAN 2007, DOI: 10.1111/j.1463-1326.2006.00700.x

  4. Thiazolidinediones and congestive heart failure in veterans with type 2 diabetes

    Diabetes, Obesity and Metabolism

    Volume 13, Issue 3, March 2011, Pages: 276–280, A. Toprani and V. Fonseca

    Version of Record online : 24 JAN 2011, DOI: 10.1111/j.1463-1326.2010.01348.x

    Corrected by:

    Corrigendum

    Vol. 14, Issue 4, 386, Version of Record online: 5 MAR 2012

  5. You have full text access to this OnlineOpen article
    The relationship between risk of bias criteria, research outcomes, and study sponsorship in a cohort of preclinical thiazolidinedione animal studies: a meta-analysis

    Evidence-based Preclinical Medicine

    Volume 1, Issue 1, December 2014, Pages: 11–20, M. Abdel-Sattar, D. Krauth, A. Anglemyer and L. Bero

    Version of Record online : 20 JAN 2015, DOI: 10.1002/ebm2.5

  6. Thiazolidinediones and the risk of incident congestive heart failure among patients with type 2 diabetes mellitus

    Pharmacoepidemiology and Drug Safety

    Volume 20, Issue 8, August 2011, Pages: 785–796, Kristian B. Filion, Lawrence Joseph, Jean-François Boivin, Samy Suissa and James M. Brophy

    Version of Record online : 13 JUN 2011, DOI: 10.1002/pds.2165

  7. You have free access to this content
    Thiazolidinediones inhibit hepatocarcinogenesis in hepatitis B virus–transgenic mice by peroxisome proliferator-activated receptor γ–independent regulation of nucleophosmin

    Hepatology

    Volume 52, Issue 2, August 2010, Pages: 493–505, Andrea Galli, Elisabetta Ceni, Tommaso Mello, Simone Polvani, Mirko Tarocchi, Francesca Buccoliero, Francesca Lisi, Laura Cioni, Barbara Ottanelli, Valeria Foresta, Guido Mastrobuoni, Gloriano Moneti, Giuseppe Pieraccini, Calogero Surrenti and Stefano Milani

    Version of Record online : 15 MAR 2010, DOI: 10.1002/hep.23669

  8. Rotational co-culture of clonal β-cells with endothelial cells: effect of PPAR-γ agonism in vitro on insulin and VEGF secretion

    Diabetes, Obesity and Metabolism

    Volume 13, Issue 7, July 2011, Pages: 662–668, M. B. Paget, H. E. Murray, C. J. Bailey, P. R. Flatt and R. Downing

    Version of Record online : 24 MAY 2011, DOI: 10.1111/j.1463-1326.2011.01392.x

  9. You have free access to this content
    Altering PPARγ Ligand Selectivity Impairs Adipogenesis by Thiazolidinediones But Not Hormonal Inducers

    Obesity

    Volume 17, Issue 5, May 2009, Pages: 965–972, Shanika P. Samarasinghe, Maria M. Sutanto, Arpad M. Danos, Daniel N. Johnson, Matthew J. Brady and Ronald N. Cohen

    Version of Record online : 6 SEP 2012, DOI: 10.1038/oby.2008.629

  10. Rosiglitazone and pioglitazone increase fracture risk in women and men with type 2 diabetes

    Diabetes, Obesity and Metabolism

    Volume 12, Issue 8, August 2010, Pages: 716–721, R. E. Aubert, V. Herrera, W. Chen, S. M. Haffner and M. Pendergrass

    Version of Record online : 23 MAR 2010, DOI: 10.1111/j.1463-1326.2010.01225.x

  11. Synthesis of New N-Substituted 5-Arylidene-2,4-thiazolidinediones as Anti-Inflammatory and Antimicrobial Agents

    Archiv der Pharmazie

    Volume 346, Issue 6, June 2013, Pages: 481–490, Cristina Nastasă, Brînduşa Tiperciuc, Alina Pârvu, Mihaela Duma, Ioana Ionuţ and Ovidiu Oniga

    Version of Record online : 13 MAY 2013, DOI: 10.1002/ardp.201300021

  12. Comparison of vildagliptin and thiazolidinedione as add-on therapy in patients inadequately controlled with metformin: results of the GALIANT trial – a primary care, type 2 diabetes study

    Diabetes, Obesity and Metabolism

    Volume 11, Issue 10, October 2009, Pages: 978–986, L. Blonde, S. Dagogo-Jack, M. A. Banerji, R. E. Pratley, A. Marcellari, R. Braceras, D. Purkayastha and M. Baron

    Version of Record online : 13 JUL 2009, DOI: 10.1111/j.1463-1326.2009.01080.x

  13. Treatment escalation options for patients with type 2 diabetes after failure of exenatide twice daily or glimepiride added to metformin: results from the prospective European Exenatide (EUREXA) study

    Diabetes, Obesity and Metabolism

    Volume 17, Issue 7, July 2015, Pages: 689–698, G. Schernthaner, J. Rosas-Guzmán, F. Dotta, B. Guerci, R. Simó, A. Festa, J. Kiljański, M. Zhou and B. Gallwitz

    Version of Record online : 8 MAY 2015, DOI: 10.1111/dom.12471

  14. Thiazolidinedione-induced skeletal fragility – mechanisms and implications

    Diabetes, Obesity and Metabolism

    Volume 11, Issue 4, April 2009, Pages: 275–284, Andrew Grey

    Version of Record online : 30 JUL 2008, DOI: 10.1111/j.1463-1326.2008.00931.x

  15. You have free access to this content
    An Insulin-Sensitizing Thiazolidinedione, Which Minimally Activates PPARγ, Does Not Cause Bone Loss

    Journal of Bone and Mineral Research

    Volume 30, Issue 3, March 2015, Pages: 481–488, Tomohiro Fukunaga, Wei Zou, Nidhi Rohatgi, Jerry R Colca and Steven L Teitelbaum

    Version of Record online : 16 FEB 2015, DOI: 10.1002/jbmr.2364

  16. A placebo-controlled trial of exenatide twice-daily added to thiazolidinediones alone or in combination with metformin

    Diabetes, Obesity and Metabolism

    Volume 12, Issue 12, December 2010, Pages: 1058–1065, J. Liutkus, J. Rosas Guzman, P. Norwood, L. Pop, J. Northrup, D. Cao and M. Trautmann

    Version of Record online : 26 OCT 2010, DOI: 10.1111/j.1463-1326.2010.01251.x

  17. Cancer risks in thiazolidinedione users compared to other anti-diabetic agents

    Pharmacoepidemiology and Drug Safety

    Volume 16, Issue 5, May 2007, Pages: 485–492, Carol Koro, Steven Barrett and Nawab Qizilbash

    Version of Record online : 27 DEC 2006, DOI: 10.1002/pds.1352

  18. Searching for the right outcome? A systematic review and meta-analysis of controlled trials using carotid intima-media thickness or pulse wave velocity to infer antiatherogenic properties of thiazolidinediones

    Diabetes, Obesity and Metabolism

    Volume 12, Issue 2, February 2010, Pages: 124–132, D. R. Webb, M. J. Davies, L. J. Gray, K. R. Abrams, B. Srinivasan, S. Das, N. Taub, I. Lawrence, S. Sutton and K. Khunti

    Version of Record online : 17 NOV 2009, DOI: 10.1111/j.1463-1326.2009.01122.x

  19. Thiazolidinediones exhibit different effects on preadipocytes isolated from rat mesenteric fat tissue and cell line 3T3-L1 cells derived from mice

    Cell Biology International

    Volume 31, Issue 7, July 2007, Pages: 703–710, Hitoshi Mineo, Chikako Oda, Hideyuki Chiji, Teruo Kawada, Kyoko Shimizu and Toshio Taira

    Version of Record online : 2 JAN 2013, DOI: 10.1016/j.cellbi.2007.01.002

  20. The effect of thiazolidinediones on adiponectin serum level: a meta-analysis

    Diabetes, Obesity and Metabolism

    Volume 10, Issue 5, May 2008, Pages: 367–375, N. Riera-Guardia and D. Rothenbacher

    Version of Record online : 21 JUL 2007, DOI: 10.1111/j.1463-1326.2007.00755.x